Medicilon won the "Best Strategic Partner" award from NewDEL Biotech in 2023

Shanghai Medicilon Inc. (Medicilon) has recently won the "Best Partner Award" from Gluetacs Therapeutics and the "2003 Best Partner Award" from SicaGene.

On January 29, Medicilon was awarded the 2023 "Best Strategic Partner" award by NewDEL Biotech.

Trust makes each other successful, Collaboration creates the future

NewDEL Biotech is the first biopharmaceutical company incubated by the Guangdong Small Molecule New Drug Innovation Center (Small Molecule Center). Relying on the independently developed "SmartDEL technology platform" and unique living cell screening technology, a full life cycle system for innovative drugs focusing on the design, development and industrialization of FIC innovative drugs has been established to target unmet clinical needs. In addition, dozens of R&D pipelines have been laid out. It can be said that "innovation" has become the foundation and confidence for the development of NewDEL Biology.

Like NewDEL Biotech, Medicilon also adheres to integrity and innovation, and has successfully established a one-stop biopharmaceutical preclinical R&D service platform. Relying on this platform, Medicilon has provided strong support for the research and development of new drugs by NewDEL Biotech. Since the collaboration, the two parties have faced many challenges, made a lot of gratifying progress, and moved forward together.

Find more about Preclinical Research Platform:

https://www.medicilon.com/platform/preclinical-research-services/

About NewDEL Biotech

NewDEL Biotech was established in April 2021. It is an industrialized company incubated and controlled by the Guangdong Small Molecule New Drug Innovation Center. Relying on its independently developed "SmartDEL technology platform" and unique living cell screening technology, NewDEL Biotech has established a full life cycle system for innovative drugs focusing on the design, development and industrialization of FIC innovative drugs for unmet clinical needs. NewDEL Biotech committed to become an internationally leading and distinctive new drug R&D biopharmaceutical company.

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. By the end of June 2023, Medicilon has provided new drug R&D services to more than 2,000 clients around the world, and participated in the R&D of 420 new drug projects that have been approved for clinical trials. Medicilon is proud to contribute to human health in the globe.

In Vitro Enzyme Activity Assay

Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+ in vitro enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

阅读全文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

阅读全文

Pharmacokinetics Services

Pharmacokinetics Services Our pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody. The animal species involved in our services are non-human primate, canine, mice, rat, rabbit and hamster. Meanwhile, non-human primate experimental platform and isotope platform for protein/antibody are certified by the Shanghai government. Preclinical Pharmacokinetics Method development and validation (GLP,Non-GLP) Bioanalysis Pharmacokinetics (Tumor bearing rodents, Bioavailability, Crossover studies, Cassette (N in 1) dosing and analysis, effects of gender on pharmacokinetics, BBB penetration ) Stability in vehicles and plasma Drug interaction studies In vitro metabolic stability CYP 450 inhibition Plasma protein binding studies Distribution studies Excretion studies Prediction an...

阅读全文

Shanghai Medicilon Inc.

搜索此博客